Clinical Trials in Miramar, Florida
20 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche425 enrolled173 locationsNCT06819891
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Novo Nordisk A/S270 enrolled63 locationsNCT07415954
Recruiting
Phase 2
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Clostridioides Difficile Infection
AstraZeneca230 enrolled114 locationsNCT07285213
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Heart FailureAcute Heart Failure
Colorado Prevention Center5,200 enrolled299 locationsNCT06008197
Recruiting
Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular Disease
Amgen11,000 enrolled243 locationsNCT07136012
Recruiting
Phase 2
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Regeneron Pharmaceuticals270 enrolled47 locationsNCT07271186
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 2
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Type 2 Diabetes
Housey Healthcare ULC300 enrolled25 locationsNCT07546929
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung Cancer
Bayer444 enrolled283 locationsNCT06452277
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 3
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Phase 3
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Phase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Sanofi208 enrolled69 locationsNCT07170917
Recruiting
Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Obesity
Novo Nordisk A/S1,150 enrolled72 locationsNCT07339423
Recruiting
Phase 3
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals400 enrolled114 locationsNCT06868212
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
Lysosomal Acid Lipase DeficiencyWolman DiseaseCholesterol Ester Storage Disease+4 more
Alexion Pharmaceuticals, Inc.300 enrolled104 locationsNCT01633489
Recruiting
Not Applicable
Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain
NeuropathyNeuropathy;Peripheral
Erchonia Corporation32 enrolled1 locationNCT06912646
Recruiting
Phase 2
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Atopic Dermatitis (AD)
CAGE Bio Inc.180 enrolled16 locationsNCT06810050